Compare BLND & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLND | BWAY |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Israel |
| Employees | 540 | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.4M | 450.8M |
| IPO Year | 2021 | N/A |
| Metric | BLND | BWAY |
|---|---|---|
| Price | $1.72 | $24.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $4.80 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 3.3M | 79.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $162,019,000.00 | N/A |
| Revenue This Year | N/A | $314.08 |
| Revenue Next Year | $19.81 | $23.37 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | ★ 3.30 | N/A |
| 52 Week Low | $1.57 | $7.84 |
| 52 Week High | $4.49 | $26.63 |
| Indicator | BLND | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 32.56 | 52.86 |
| Support Level | N/A | $14.79 |
| Resistance Level | $3.73 | $25.71 |
| Average True Range (ATR) | 0.12 | 1.39 |
| MACD | 0.03 | -0.15 |
| Stochastic Oscillator | 28.72 | 35.03 |
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.